126325-47-1

Basic information

• Product Name: 5-Amino-2-bromo-6-picoline
• Synonyms: 3-AMINO-6-BROMO-2-METHYLPYRIDINE;3-AMINO-6-BROMO-2-PICOLINE;6-BROMO-2-METHYL-PYRIDIN-3-YLAMINE;2-Bromo-5-amino-6-methylpyridine;6-Bromo-5-amino-2-picoline;6-BROMO-3-AMINO-2-PICOLINE (5-AMINO-2-BROMO-6-PICOLINE);5-AMINO-2-BROMO-6-PICOLINE (5-AMINO-2-BROMO-6-METHYLPYRIDINE);6-bromo-2-methylpyridine-3-amine
• CAS NO: 126325-47-1
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.04
• EINECS: 251-156-6
• Product Categories: Pyridine;Pyridines;Boronic Acid;Amino-pyridine series;Heterocycle-Pyridine series
• Mol File: 126325-47-1.mol

Chemical Properties

• Melting Point: 110-111℃
• Boiling Point: 284.4 °C at 760 mmHg
• Flash Point: 125.8 °C
• Appearance: Off-white/Solid
• Density: 1.593 g/cm³
• Vapor Pressure: 0.00298mmHg at 25°C
• Refractive Index: 1.617
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.45±0.10(Predicted)
• CAS DataBase Reference: 5-Amino-2-bromo-6-picoline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-2-bromo-6-picoline(126325-47-1)
• EPA Substance Registry System: 5-Amino-2-bromo-6-picoline(126325-47-1)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-41-37/38-22
• Safety Statements: 26-36-39
• Hazardous Substances Data: 126325-47-1(Hazardous Substances Data)

Usage

Uses

Used in Research and Development:
5-Amino-2-bromo-6-picoline is used as a research intermediate for the synthesis of various chemical compounds and pharmaceuticals. Its unique structure allows it to serve as a building block in the development of new molecules with specific properties and applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Amino-2-bromo-6-picoline is used as a key intermediate in the synthesis of drugs targeting specific medical conditions. Its chemical properties make it a valuable component in the creation of novel therapeutic agents.
Used in Chemical Synthesis:
5-Amino-2-bromo-6-picoline is utilized as a starting material in the synthesis of various organic compounds, including those with potential applications in materials science, agrochemicals, and other specialty chemicals.
Used in Analytical Chemistry:
5-Amino-2-bromo-6-picoline can also be employed in analytical chemistry as a reference material or for the development of new analytical methods, given its distinct chemical and physical properties.

InChI:InChI=1/C6H7BrN2/c1-4-5(8)2-3-6(7)9-4/h2-3H,8H2,1H3

Upstream product

• 22282-96-8 6-bromo-2-methyl-3-nitro-pyridine 
• 3430-10-2 2-methyl-3-pyridinamine 

Downstream Products

• 42451-07-0 6-ethyl-2-methylpyridin-3-ol 
• 1956379-02-4 5,7-dibromo-1H-pyrazolo[4,3-b]pyridine 
• 1227628-78-5 5-bromo-1H-pyrazolo[4,3-b]pyridine 
• 1079054-78-6 5-amino-6-methylpicolinonitrile 
• 1400926-88-6 (7aS,9R,11aS)-11a-benzyl-9-ethyl-9-hydroxy-6,7,7a,8,9,10,11,11a-octahydro-5H-dibenzo[a,c]cycloheptene-3-carboxylic acid (6-bromo-2-methyl-pyridin-3-yl)-amide 
• 897732-75-1 2-methyl-6-(methylsulfonyl)pyridin-3-amine 
• 944317-27-5 6-bromo-3-chloro-2-methylpyridine 

Relevant articles and documents

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to the use of 1 H-imidazo[4,5-c]quinolinone compounds and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1 H-imidazo[4,5-c]quinolinone compounds for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1 H-imidazo[4,5-c]quinolinone compounds to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1 H-imidazo[4,5-c]quinolinone compounds, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H-imidazo[4,5-c]quinolinone compounds; and a process for the preparation of the novel 1 H-imidazo[4,5-c]quinolinone compounds.

Bromination of Pyridines. II. Bromination of Aminopicolines

The bromination of all ten possible aminopicolines 1-10 was investigated.In general, the major brominated product was that corresponding to electrophilic attack at the sites para or ortho to the amino group.